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Abstract
Aims—Diabetic retinopathy (DR) is associated with a higher risk of renal and cardiovascular 
events. We sought to compare the risk for renal versus cardiovascular (CV) outcomes, stratified by 
retinopathy severity.
Methods—ACCORD was a randomized trial of people with type 2 diabetes, at high-risk for CV 
disease. A subgroup (n=3,369 from 71 clinics) had stereoscopic fundus photographs graded 
centrally. Participants were stratified at baseline to moderate/severe DR or no/mild DR and were 
monitored for renal and CV outcomes at follow-up visits over 4 years. The composite renal 
outcome was comprised of serum creatinine doubling, macroalbuminuria, or end-stage renal 
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disease. The composite CV outcome was the ACCORD trial primary outcome. Competing risk 
techniques were used to estimate the relative risk (RR) of renal versus CV composite outcomes 
within each DR stratum.
Results—The hazards ratio for doubling of serum creatinine and incident CV event in the 
moderate/severe DR versus no/mild DR strata were: 2.31 (95%CI: 1.25–4.26) and 1.98 (95%CI: 
1.49–2.62), respectively. The RR of the two composite outcomes was highly similar in the no/mild 
DR stratum (adjusted RR at 4 years for CV versus renal events=0.96, 95%CI:0.72–1.28) and the 
moderate/severe DR stratum (adjusted RR=0.92, 95%CI:0.64–1.31).
Conclusions—Thus, in people with type 2 diabetes at high risk for cardiovascular disease, 
incident CV versus renal events was similar, irrespective of the severity of the DR. Further 
evaluation of the specificity of DR for microvascular versus macrovascular events in other 
populations is warranted.
Keywords
retinopathy; nephropathy; macrovascular; albuminuria
INTRODUCTION
Diabetic microvascular complications of the eye and kidney are similar in their risk factor 
profiles and share some mechanisms in their pathogenesis.(Brownlee, 2005; Ravid et al., 
1998; Yau et al., 2012) Numerous studies have examined the association of retinopathy with 
diabetic kidney disease, but the vast majority of these have been of cross sectional design. In 
type 2 diabetes, the presence versus absence of any diabetic retinopathy (DR) gives an 
adjusted odds ratio of between 2.5 and 3.3 for the presence of macroalbuminuria (defined as 
a urine albumin:creatinine ratio > 300ug/mg).(El-Asrar et al., 2001; Romero-Aroca et al., 
2010) Similar results have been obtained in studies examining the association of DR with 
decreased estimated glomerular filtration rate (eGFR), defined as <60ml/min/1.73m2.(Mottl 
et al., 2012; Penno et al., 2012) In a step-wise fashion, more severe retinopathy is 
increasingly associated with diabetic kidney disease. The presence of proliferative 
retinopathy carries an odds ratio for concurrent macroalbuminuria or decreased eGFR as 
high as 17-fold.(El-Asrar et al., 2001; Mottl et al., 2012)
A strong relationship between DR and cardiovascular (CV) disease has also been well 
established. In prospective observational cohorts of people with type 2 diabetes, the 
presence of any DR versus no DR is associated with an adjusted hazard ratios of 2.3 for 
stroke,(Cheung, Rogers, et al., 2007) 2.5 for heart failure,(Cheung et al., 2008) and 2.2–3.3 
for cardiovascular death.(Cheung, Wang, et al., 2007; Liew et al., 2009) Longitudinal 
studies have found more severe retinopathy to result in adjusted hazard ratios of 1.7–3.8 for 
combined fatal and nonfatal ischemic CV endpoints.(Cheung, Wang, et al., 2007; Gerstein et 
al., 2012; Gimeno-Orna et al., 2009; Targher et al., 2008)
The similarity in risk estimates for diabetic kidney and CV outcomes in the setting of 
retinopathy might suggest a similar or shared pathogenesis for micro- and macrovascular 
complications of diabetes. Although an overlap in their pathobiology likely exists, there are 
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also data to suggest there is some distinction. The association between retinopathy and CV 
events has been noted to be of similar magnitude, regardless of diabetes type,(Kramer et al., 
2011) however, the link between retinopathy and nephropathy is considered to be 
significantly greater in type 1 versus type 2 diabetes.(Wolf et al., 2007) It has been 
suggested that kidney disease in type 2 diabetes is more heterogeneous than in type 1 
diabetes, with a greater prevalence of tubulointerstitial versus glomerular lesions,(Fioretto et 
al., 1996) and a higher prevalence of normoalbuminuric chronic kidney disease (NA-CKD).
(Macisaac & Jerums, 2011) Whether these distinctions in the clinical and pathologic 
characteristics in type 2 diabetes explain the weaker association of retinopathy with kidney 
disease than in type 1 diabetes is unknown.
Given the uncertainty over the specificity of DR for renal versus CV disease, we sought to 
compare the relative incidence of these events according to the severity of retinopathy. 
Detailed analyses of the association of DR with incident CV events in the ACCORD trial 
have been previously published.(Gerstein et al., 2012) Given the assumption that DR has 
greater overlap in pathogenesis with other diabetic microvascular complications, such as 
kidney disease, we hypothesized that kidney outcomes should occur at a greater relative 
frequency compared to CV outcomes in participants with more severe retinopathy. A 
simplistic approach to this question could include fitting separate survival models for kidney 
and CV outcomes, using the resulting hazard ratios to compare associations with DR, 
however, such a comparison ignores the increased risk of CV events associated with the 
development of chronic kidney disease (CKD).(Hemmelgarn et al., 2010; Weiner et al., 
2004) In circumstances where one event modifies the risk for another event, treating the 
outcomes as competing risks can be more appropriate.(Noordzij et al., 2013) Therefore in 
the present study, we used competing risks techniques to compare the relative incidence of 
CV and renal outcomes, focusing on which event occurs first in subgroups of participants 
from the ACCORD trial, stratified by severity of DR.
SUBJECTS, MATERIALS AND METHODS
Study Population
The design of the ACCORD trial and ACCORD Eye Study have been previously reported.
(Buse et al., 2007; Chew et al., 2007) Briefly, middle-aged and elderly people with type 2 
diabetes, hemoglobin A1c (HbA1c) levels ≥ 7.5% and known CV disease or additional CV 
risk factors were recruited from 77 clinical centers. Exclusion criteria included BMI > 
45kg/m2 and SCr > 132.6 µmol/L (1.5mg/dL). Participants were randomized to the intensive 
glucose-lowering trial as well as an intensive blood pressure-lowering or fibrate trial. The 
primary trial outcome consisted of a composite of fatal and nonfatal CV events and all-cause 
mortality. Events were ascertained every 4 months. The mean follow-up time for 
cardiovascular events and mortality was 4.7 and 5.0 years, respectively. ACCORD 
participants who did not have a history of proliferative DR treated with laser 
photocoagulation or vitrectomy were eligible to also participate in the ACCORD Eye Study. 
All Eye Study participants provided written informed consent for both the ACCORD trial 
and the Eye Study.
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The baseline eye assessment consisted of standardized eye examination with fundus 
photography of seven standard stereoscopic fields. Fundus photographs were evaluated 
centrally by trained graders according to the modified version of the ETDRS Final Diabetic 
Retinopathy Severity Scale, which combines the severity levels from both eyes.(Early 
Treatment Diabetic Retinopathy Study (ETDRS) criteria, 1991) The severity was classified 
as no retinopathy, mild nonproliferative diabetic retinopathy (NPDR), moderate NPDR and 
severe retinopathy (severe NPDR or proliferative retinopathy).
Participants were evaluated every four months to obtain information on study outcomes, 
perform clinical examination and to collect fasting blood samples.(Buse et al., 2007) Single, 
random urine specimens were collected every 24 months for urine albumin and creatinine 
measurements.
Statistical Analysis
Statistical analyses were performed using SAS software (Version 9.2 for Windows) and the 
R Statistical Computing Environment.(R Core Team, 2012) Descriptive statistics were 
calculated and compared according to the severity of baseline retinopathy using Analysis of 
Variance (ANOVA), Kruskal-Wallis tests, or Chi-squared tests, as appropriate. 
Microalbuminuria was defined as a urine albumin creatinine ratio (UACR) of ≥ 30µg/mg 
and macroalbuminuria as a UACR of ≥ 300 µg/mg.("Standards of medical care in 
diabetes--2011," 2011) Estimated GFR (eGFR) was calculated using the Chronic Kidney 
Disease Epidemiology (CKD-EPI) equation.(Levey et al., 2009) ESRD was defined as an 
eGFR <15ml/min/1.73m2 or if a participant was on dialysis or received renal 
transplantation.
Cox proportional hazards (PH) regression models were used to examine the effect of 
retinopathy (classified as no/mild DR versus moderate/severe DR) on 1) the composite renal 
outcome: doubling of SCr or incident macroalbuminuria (≥300µg/mg) or ESRD or 2) the 
CV composite outcome (which was the same as the primary outcome of the ACCORD 
clinical trial): incident myocardial infarct or stroke and CV death. Secondary outcomes 
included each of the individual outcomes which comprised the composite outcomes.
Given the current debate concerning the suitability of doubling of SCr and incident 
macroalbuminuria as surrogate endpoints for ESRD,(Lambers Heerspink et al., 2011) we 
defined these outcomes to exclude transient changes in kidney function. We required that a 
doubling of SCr was observed at two consecutive study visits, with SCr levels remaining 
above a 100% increase for the remainder of available follow-up. We imposed a similar 
requirement for incident macroalbuminuria, only considering outcomes where the UACR 
remained above 300 µg/g at all subsequent follow-up visits. Because the UACR was only 
measured at yearly follow-up visits in ACCORD, a significant proportion of incident 
macroalbuminuria cases were only observed at the final study visit (72/129=55.8%). 
Because of the relatively low overall incidence of macroalbuminuria in ACCORD, we did 
not remove such cases from this revised definition of incident macroalbuminuria.
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For the composite outcomes, we included the following factors as covariates in the Cox 
regression models: age (modeled as a quadratic polynomial), gender, non-white ethnicity, 
BMI, SBP, hemoglobin A1C, diabetes duration, history of a prior CV event, participation in 
the lipid trial, allocation to the intensive glycemia group, allocation to the intensive blood 
pressure group, allocation to fenofibrate, and indicators to adjust for effects across the 7 
clinical center networks in ACCORD. We evaluated the PH assumption using hypothesis 
tests based on the scaled Schoenfeld residuals.(Grambsch & Therneau, 1994) We did not 
observe any strong deviations from PH for either retinopathy status or any of the covariates 
considered.
We used the competing risk regression framework of Fine and Gray(Fine & Gray, 1999) to 
compare the cumulative incidence of kidney disease outcomes versus CV outcomes within 
each DR stratum. In the competing risk regression framework, we utilized a stratified 
version of the Fine and Gray model so as not to assume that the differences in cumulative 
incidence functions across DR strata were time invariant. Comparisons between cumulative 
incidence functions at a specific point in time (4 years of follow-up) are presented as relative 
risks, as described in Zhang and Fine. We used the approach of Zhang and Zhang(Zhang & 
Zhang, 2011) to produce direct adjusted estimates of the respective cumulative incidence 
functions, using the same set of covariates included in the Cox regression models described 
above.
RESULTS
Of the 3,472 participants recruited for the ACCORD Eye Study, 3,210 had complete 
baseline covariate data and complete follow-up for both kidney and cardiovascular 
outcomes. At baseline, 1,628, 587, 955 and 40 participants had no, mild, moderate, and 
severe DR, respectively. Sociodemographic and clinical characteristics of the participants, 
stratified by category of DR severity are displayed in Table 1. The prevalence of macular 
edema did not differ amongst the four categories of DR. The majority of participants were 
male and in their sixth decade of age. The mean duration of diabetes increased with 
worsening severity of DR from 6 years in those with no DR to 15 years in those with severe 
DR. Similarly, both systolic and diastolic blood pressures, HbA1c, BMI and UACR tended 
to be increasingly higher with worse categories of retinopathy severity. ACEI/ARB use 
increased with increasing severity of DR from 63.4% in those without DR to 80% in those 
with severe DR. A similar trend is observed for other clinical characteristics such as the 
prevalence of micro and macroalbuminuria and previous CV event. Estimated GFR (eGFR) 
was not statistically different between DR categories, nor were randomization to the three 
treatment arms of the trial. For individual renal and CV outcomes, participants in the 
moderate/severe DR status had unadjusted hazard ratios (HR) of 2.58, 2.31, and 1.98 for 
incident macroalbuminuria, doubling of SCr, and nonfatal CV events, respectively (Table 2). 
We also examined the relationship of severity of DR with incidence of non-CV-related 
deaths. There was a trend for a greater HR for cardiovascular and nonvascular death with 
worse DR, but these did not reach statistical significance.
Figure 1 displays estimates of the cumulative incidence curves for the competing composite 
renal and CV outcomes, stratified by retinopathy status. Within each DR strata, the adjusted 
Mottl et al. Page 5






















RRs of the CV versus renal composite outcome were not statistically different: 0.96 (95% 
CI: 0.72–1.28) for no/mild DR and 0.92 (95% CI: 0.64–1.31) for moderate/severe DR 
(Table 3). Results from competing risks modeling of the individual components of the 
composite CV and renal outcomes are also listed in table 3.
DISCUSSION
The novel finding in this study is that the incidence of CV versus renal endpoints was not 
different within strata of retinopathy status, indicating a similar strength in the association of 
retinopathy with renal versus CV outcomes. Comparison of kidney and CV outcomes is 
complex, as kidney disease is a strong risk factor for CV events(Hemmelgarn et al., 2010) 
and death often occurs prior to the progression of renal failure.(Adler et al., 2003) The use of 
a competing risk model takes both of these issues into consideration and although there did 
appear to be a trend toward greater kidney than CV outcomes in the more severe retinopathy 
stratum, this did not yield statistical significance. This may be due, in part, to the diabetic 
phenotype assembled by the inclusion criteria of ACCORD, which selected for older, type 2 
diabetic persons at high risk for CV disease and low risk for severe kidney disease.(Buse et 
al., 2007) Whether this would hold true in type 1 diabetes and/or younger cohorts requires 
further investigation.
In type 2 diabetes, retinopathy and CV disease are more highly prevalent in those with low 
eGFR (<60ml/min/1.73m2) if they have the albuminuric rather than normoalbuminuric 
phenotype.(Penno et al., 2012; Rigalleau et al., 2007; Thomas et al., 2009) 
Macroalbuminuria without low eGFR also appears to be more tightly linked to retinopathy 
than NA-CKD, but the same may not hold true for CV events. In a cross sectional Japanese 
study of type 2 diabetes, participants with no albuminuria but decreased eGFR < 60ml/min/
1.73m2 had a lower odds of having retinopathy than people with macroalbuminuria and 
eGFR > 60ml/min/1.73m2 (OR=0.51; 95%CI 0.27–0.97).(Ito et al., 2010) Conversely, there 
was no real difference in history of coronary or cerebrovascular disease between these two 
groups, OR=1.70 (95%CI 0.83–3.47) and OR=0.75 (95%CI 0.39–1.41), respectively. 
Extrapolating this information to the present study, one would have expected a greater RR 
for incident macroalbuminuria versus cardiovascular endpoints in the moderate/severe 
retinopathy stratum compared to the no/mild retinopathy stratum. The similar risk of 
incident macroalbuminuria versus cardiovascular events between the two DR strata in this 
study may be due to the inclusion criteria of ACCORD which selected for people with 
preexisting or at extremely high risk for CVD. Such high CVD risk may overpower any 
increased association between DR and macroalbuminuria in a more general population.
Another finding underscored by our analyses is that with use of a longitudinal study design 
and robust endpoints for diabetic kidney disease, more severe retinopathy remains 
significantly predictive of greater risk for subsequent renal outcomes. Multiple previous 
studies have demonstrated the association between diabetic complications of the eye and 
kidney, however, most have been cross sectional(Cruickshanks et al., 1993; Grunwald et al., 
2012; Penno et al., 2012; Romero-Aroca et al., 2010) and longitudinal studies have rarely 
used hard clinical renal endpoints. Our hazard ratios of more severe retinopathy for renal 
endpoints was similar to those reached in cross sectional analyses and also those using less 
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robust definitions for kidney outcomes. In agreement with our study, the Early Treatment for 
Diabetic Retinopathy Study (ETDRS) also found that over five years of follow-up, people 
with type 2 diabetes and baseline severe DR versus mild/moderate DR at baseline have a 
60% higher risk for subsequent end-stage renal disease (ESRD) requiring renal replacement 
therapy.(Cusick et al., 2004)
It is possible that ACCORD’s very robust definition for CV events underestimated the 
association between retinopathy and CV disease. ACCORD did not include hospitalization 
for CHF or incident angina in the primary outcome. The same holds true with respect to our 
definition of renal outcomes, as we did not include incident microalbuminuria or sustained 
increases creatinine that were smaller than doubling. Hence, a number of design issues may 
be skewing our results towards a stronger association between DR and either CV or renal 
events.
Also limiting our analyses is that competing risks models approach the issue of specificity 
for renal and CV outcomes by asking which event happens first. An ideal analysis would 
have been the use of a multi-state model,(Putter et al., 2007) whereby renal and non-fatal 
CV events could be viewed as intermediate outcomes. This would permit evaluating how the 
risk of CV events changes if they are preceded by progression of kidney disease, or vice 
versa. However, over 90% of the renal and CV events observed during the primary follow-
up period for the ACCORD trial were “first events”, and so there are an insufficient number 
of events with which to estimate such a multi-state model. The question of specificity of DR 
should likely be revisited once data from the extended follow-up of ACCORD participants is 
available.(" Action to control cardiovascular risk in diabetes (accord) follow-up study,")
The strengths of this study include its large number of participants, longitudinal study 
design, standardized central reading of fundus photographs, systematic ascertainment of CV 
events and robust renal outcomes. Although albuminuria measurements were taken from a 
single, random urine specimen, we attempted to impose criteria such that the 
macroalbuminuria threshold had to be persistent throughout subsequent measurements. 
However, we did not exclude events where a UACR > 300 µg/g was only observed at the 
final study visit (see METHODS). Thus while we attempted to restrict the definition of 
macroalbuminuria so that it reflected true pathologic kidney disease, we cannot rule out that 
a proportion of these events simply reflect a transient, reversible change in albuminuria. 
Similarly, doubling of baseline SCr had to be maintained throughout subsequent visits in 
order to qualify as a renal outcome, and hence fluctuations due to changes in diet, 
medications or volume status likely did not diminish the reliability of this endpoint.
To our knowledge, this is the first study to quantify and compare the strength of association 
of retinopathy with incident renal versus CV events. Our finding that more severe 
retinopathy is equally specific for incident macroalbuminuria, doubling of SCr, and 
cardiovascular endpoints suggests these three entities may have overlapping 
pathophysiologic mechanisms. Whether there is a distinction between micro and 
macrovascular diabetic complications in other populations requires further study.
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Cumulative incidence curves for the competing risks of the renal composite outcome* (solid 
lines) and ACCORD primary outcome† (dashed lines) during follow-up according to 
baseline retinopathy status. Plot excludes individuals with macroalbuminuria at 
baseline.*Renal composite outcome includes sustained doubling of serum creatinine, 
incident macroalbuminuria (≥300µg/mg), or ESRD. †ACCORD primary outcome includes 
incident myocardial infarct or stroke or CV death.
Mottl et al. Page 11


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Mottl et al. Page 14
Table 2
Renal, macrovascular and composite outcomes stratified by baseline severity of retinopathy in 3,210 









Sustained incident macroalbuminuriaa 61/2128(2.9) 68/901(7.5) 2.58(1.83–3.65)
Sustained doubling of Baseline serum creatinine 20/2215(0.9) 21/995(2.1) 2.31(1.25–4.26)
End stage renal diseaseb 48/2215(2.2) 23/995(2.3) 1.05(0.64–1.73)
Incident cardiovascular eventc 103/2215(4.7) 91/995(9.1) 1.98(1.49–2.62)
Cardiovascular death 24/2215(1.1) 14/995(1.4) 1.24(0.64–2.39)
Nonvascular death 36/2215(1.6) 19/995(1.9) 1.15(0.66–2.00)
a
Urine albumin:creatinine ≥ 300µg/mg, excluding individuals with baseline macroalbuminuria
b
Estimated glomerular filtration rate < 15ml/min/1.73m2 using the Chronic Kidney Disease-Epi equation or requiring dialysis or renal 
transplantation
c
Nonfatal myocardial infarction or stroke
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